Sebacia Postmarket Study of Real-World Use

A Prospective, Multicenter, Postmarket Study of Sebacia Microparticles Treatment in Patients Using Topical Acne Products for Mild to Moderate Inflammatory Acne Vulgaris

Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.

Inclusion Criteria:

• Mild to moderate facial inflammatory acne vulgaris (IGA 2 or 3)
• Between 10 and 50 papules/pustules
• Fitzpatrick skin phototype I, II or III
• Able to provide informed consent and comply with study schedule and other requirements

Exclusion Criteria:

• Moderately severe or severe acne vulgaris (IGA 4 or 5)
• Nodulocystic acne, significant scarring or excoriation
• Requires oral retinoid, antibiotic or corticosteroid for acne
• New or fluctuating hormone or hormone-regulating therapy
• Photosensitivity or allergy to gold
• Medical or mental health condition that would pose a risk to patient or impair treatment and evaluation